2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1586 Association of body mass index with first-line response and survival outcomes in patients with newly diagnosed acute myeloid leukemia

Aishwarya Pradeep, MD, Mohamad Sheikh Najeeb2, Kristen McCullough, PharmD3, Katherine Alvarez-Wurdeman, APRN4, Matthew Clark, APRN5, Aasiya Matin, MBBS6, Abhishek Avinash Mangaonkar, MBBS7, Mehrdad Hefazi Torghabeh, MD8, Mrinal M. Patnaik, MD, MBBS9, Mithun Shah, MD, PhD10, Kebede Begna, M.D.11, Talha Badar, MD12, Rong He, MD13, Patricia Greipp, DO14, William Hogan, M.B., B.Ch.15, Dragan Jevremovic, MD PhD16, Mark R. Litzow, MD17, Cecilia Arana Yi, M.D.18, Naseema Gangat, MBBS19, James Foran, FRCPC20, Hassan B Alkhateeb, M.D.21, Tariq Kewan, MD22, Aref Al-Kali, M.D.23, Antoine N. Saliba, M.D.24
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States

Background
Body mass index (BMI) and obesity have emerged as potential modifiers of treatment outcomes in acute myeloid leukemia (AML). As many AML therapies are administered according to body surface area, extremes of body size may affect dose selection, treatment exposure, and toxicity. Obesity may also be associated with differences in comorbidity, treatment tolerance, leukemia biology, and allogeneic transplant (alloHSCT) eligibility. The prognostic significance of BMI in AML remains uncertain, with prior studies reporting conflicting associations with remission, relapse, and overall survival (OS). We evaluated associations of BMI with response to first-line therapy and OS in adult patients (pts) with newly diagnosed (ND) AML.

Methods
We retrospectively identified 624 adults diagnosed with ND AML (WHO 5th edition) between 2016-2024, at Mayo Clinic in Rochester, MN. Data were abstracted from medical records. Pts with BMI ≤18.5 kg/m2 were excluded because of small numbers. BMI was categorized as healthy weight (18.5-<25 kg/m2), overweight (25-<30), class 1 obesity (30-<35), class 2 obesity (35-<40), and class 3 obesity (≥40). The response endpoint was CRc (CR/CRh/CRi) after first-line therapy. OS was measured from diagnosis to death or last follow-up. Multivariable logistic and Cox regression models were adjusted for age, sex, ELN 2022 risk, first-line treatment intensity, and therapy-related AML. OS was estimated by Kaplan-Meier and compared by log-rank.

Results
618 pts with ND AML and BMI >18.5 kg/m2 (median age 68 years [IQR 59-75 years]; 41.6% female; 59.9% de novo, 15.5% secondary, and 24.4% therapy-related) were identified. By BMI, 144 (23.3%) had healthy weight, 221 (35.8%) were overweight, 136 (22%) had Class 1, 80 (12.9%) Class 2, and 37 (6%) Class 3 obesity, for a total of 253 (40.9%) meeting criteria for obesity (BMI≥30). Compared with non-obese pts, obese pts were more frequently female (46.6% vs 38.1%; p=0.034). ELN 2022 adverse-risk disease was numerically less prevalent in obese pts (59.4% vs 68.7%; p=0.057). TP53 mutations (19.5% vs 18.2%) and complex karyotype (26.9% vs 29.3%) were similarly distributed between obese and non-obese pts, respectively. Rates of alloHSCT were comparable in the obese (29.6%) and non-obese (35.5%) groups. The groups were otherwise similar for baseline characteristics and treatment intensity. 

Overall, CRc was higher among obese pts (63.5% vs 53.0%; adjusted OR, 1.51; 95% CI, 1.05-2.18; p=0.027) and remained higher in the evaluable-only analysis (71.2% vs 59.7%; adjusted OR, 1.60; 95% CI, 1.07-2.38; p=0.022). The 5-category BMI classification model was globally significant (p=0.048); only Class 3 obesity was independently associated with higher odds of response vs healthy weight (OR 3.58, 95% CI 1.32-9.65; p=0.012) without a consistent graded relationship across the 5 categories. An exploratory stratified analysis showed that this effect was most pronounced among pts ≥65 years (OR 1.85, 95% CI 1.16-2.96; p=0.010) and those receiving lower-intensity therapy (LIT; OR 1.82, 95% CI 1.14-2.90; p=0.012), without significant obesity-by-age or obesity-by-treatment interaction (p>0.10). Among pts achieving CRc, the cumulative incidence of relapse was similar in obese and non-obese pts at 12 months (32.2% vs 28.9%) and 36 months (46.6% vs 46.0%), respectively.

After a median follow-up of 38.6 months, median OS was 19.0 months in obese vs 16.0 months in non-obese treated pts (log-rank p=0.71). On adjusted Cox multivariable regression, obesity was not independently associated with OS (HR 0.95, 95% CI 0.76-1.18; p=0.63), nor in age- or treatment intensity-stratified models, nor after censoring at alloHSCT. Median OS among treated pts was numerically longest for Class 2 obesity (23.9 months) and shortest for Class 3 (9.8 months). The adjusted HR for Class 3 vs. healthy weight showed a numerically worse OS without reaching statistical significance (HR 1.53, 95% CI 0.95-2.46; p=0.078).

Conclusion
In our contemporary cohort of ND AML pts, obesity was independently associated with higher CRc to first-line therapy, particularly among older pts and those receiving LIT. Obesity was not associated with OS, consistent with the ECOG-ACRIN 1900/3999 analysis (Foran et al, 2023) and others (Li et al, 2017). Our data highlight potential limitations of BMI as a surrogate for body composition; future analyses will evaluate the effects of chemotherapy dose capping and sarcopenia on the observed associations.

Aishwarya Pradeep, MD: No relevant conflicts of interest to declare.